$PEPG

Buy Rating on PepGen: DM1 Program De-Risked by Stronger Underlying Biology and Upside from Higher-Dose Cohorts

H.C. Wainwright analyst Ananda Ghosh maintained a Buy rating on PepGen Inc. with a $20.00 price target. Ghosh believes PepGen's DM1 program is de-risked due to stronger underlying biology observed in treated patients, despite a modest average splicing correction skewed by an anomalous patient. The analyst anticipates significant upside from higher-dose cohorts, expecting materially higher splicing correction which could serve as a key value inflection point for the stock.

Original reporting
TipRanks · TipRanks Auto-Generated Intelligence Newsdesk
Published Apr 1, 2026, 2:39 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Apr 1, 2026, 3:01 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Buy Rating on PepGen: DM1 Program De-Risked by Stronger Underlying Biology and Upside from Higher-Dose Cohorts — source image
Decision brief

The 30-second read

$PEPGBullishHigh
01

Why it matters

The biological de-risking and analyst upgrade could catalyze stock appreciation, especially if higher-dose cohorts demonstrate significant efficacy.

02

Market read

High relevance within biotech and neuromuscular disorder sectors, with potential influence on related stocks.

03

What to watch

Potential delays in clinical development, funding issues, or competitive advances could impact stock performance despite current positive signals.

Timing: Immediate to short-term (next 1-3 months)

Background

PepGen's DM1 program targets a rare neuromuscular disorder with promising preclinical and early clinical data, now de-risked by recent biological findings.

Company-level read

Ticker impact

$PEPGBullishHigh confidence
Context

High relevance due to recent analyst upgrade and positive biological data.

Expected impact

Moderate to strong upward price movement over the next 3-6 months, contingent on clinical data confirmation.

Evidence & confidence

Strong biological signals and analyst endorsement increase likelihood of positive stock performance, supported by the potential for higher-dose efficacy.

Market effects

Positive impact on biotech and life sciences sectors, especially companies with gene therapy or neuromuscular disorder pipelines.

Primarily US-focused, with potential global interest in biotech innovation.

Moderate; biotech sector performance influences global markets but is more regionally concentrated.

Counterpoint

Biotech stocks are highly volatile; positive biological data may not translate into stock appreciation if clinical or regulatory hurdles emerge.

Key entities

  • PepGen Inc.

    Developer of gene therapy treatments for neuromuscular disorders.

  • H.C.. Wainwright

    Provided recent buy rating and price target for PEPG.

Related articles

$PEPGMed

PepGen Inc. (PEPG): Results of Operations and Financial Condition

PepGen Inc. (PEPG) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 pepg-ex99_1.htm EX-99.1 EX-99.1 PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights – DSMB recommends advancement of PGN-EDODM1 into the highest dose cohort in the FREEDOM2-DM1 study, as well as FREEDOM-OLE dose escalation from 5 mg/kg t

$ETNMed

Eaton Gains on $7-Million Contract

Eaton (NYSE:ETN) said the U.S. Air Force Research Laboratory awarded it a $7 million, 24-month contract to use quantum computing, machine learning, and advanced visualization to improve power grid resilience and protection. The work, with Infleqtion and Penn State, targets detection and response to multiple concurrent physical and cyber threats, addressing NERC N-2 contingency requirements.

$XOMMed

ExxonMobil awards McDermott engineering work for Rovuma LNG

ExxonMobil Moçambique Limitada issued McDermott Energy Solutions (UK) a letter of intent for limited engineering and procurement work on Rovuma LNG Phase 1 midstream development. The award supports planning ahead of a final investment decision expected in 2026. Rovuma LNG targets 12 modular trains totaling 18.6 mtpa, with start-up in 2031. ExxonMobil says the 30-year project could generate about $150B in revenues for Mozambique’s government.

$ESLTMed

Serbia to open joint UAV factory with Elbit in September

Serbia President Aleksandar Vucic said Serbia will open a joint UAV factory with Elbit Systems, with inauguration expected Sept 15-20. Elbit will hold 51% and Serbia’s state arms firm SDPR 49%. The factory relates to a five-year contract covering precision rockets and unmanned systems, plus ISTAR, digitization and upgrades.

$NOCMed

The Pentagon is urging defense contractors to urgently ramp up weapons production – WP

The U.S. Department of Defense, according to The Washington Post, asked defense contractors to submit within 21 days production and delivery schedules for critical systems, citing depleted stockpiles. CSIS estimates cite heavy early use of missiles and falling Patriot and THAAD inventories. The Pentagon is working with Northrop Grumman and Lockheed Martin, including a $58.6B deal to triple PAC-3 output by 2030, pending a stalled $1.15T defense budget.

$LMTMed

Pentagon pushes military contractors to accelerate production amid shortages after war on Iran

The Pentagon ordered US defense contractors to submit within 21 days plans to accelerate production of missiles and interceptors amid shortages after the first month of strikes against Iran. It cited depleted Patriot and THAAD inventories and said framework agreements with Lockheed Martin and Northrop Grumman target PAC-3 and THAAD output. Lockheed Martin received a contract up to $58.6B to triple PAC-3 production by 2030.